Alpha-synuclein and neurodegenerative diseases

Nature Reviews Neuroscience

Volumn 2, Issue 7, 2001, Pages 492-501

  Goedert, Michel ^a  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; NERVE PROTEIN; SNCA PROTEIN, HUMAN; SYNUCLEIN;

ANIMAL; DEGENERATIVE DISEASE; DIFFUSE LEWY BODY DISEASE; DISEASE MODEL; GENETICS; HUMAN; LEWY BODY; METABOLISM; MULTIGENE FAMILY; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOLOGY; REVIEW; SEQUENCE HOMOLOGY; SHY DRAGER SYNDROME;

ALPHA-SYNUCLEIN; ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE; HUMANS; LEWY BODIES; LEWY BODY DISEASE; MULTIGENE FAMILY; MULTIPLE SYSTEM ATROPHY; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS; PARKINSON DISEASE; SEQUENCE HOMOLOGY, AMINO ACID; SYNUCLEINS;

EID: 0035409575     PISSN: 14710048     EISSN: None     Source Type: Journal    
DOI: 10.1038/35081564     Document Type: Review

References (129)

1. Alzheimer, A. Über eine eigenartige Erkrankung der Himrinde. Allg. Z. Psychiatr. Psych.-Gerichtl. Med. 64, 146-148 (1907).
2. Alzheimer, A. Über eigenartige Krankheitsfälle des späteren Alters. Z. ges. Neurol. Psychiatr. 4, 356-385 (1911).
3. Lewy, F. in Handbuch der Neurologie Vol. 3 (eds Lewandowski, M. & Abelsdorff, G.) 920-933 (Springer Verlag, Berlin, 1912). The first description of the inclusions that define Parkinson's disease at a neuropathological level.
4. Kidd, M. Paired helical filaments in electron microscopy of Alzheimer's disease. Nature 197, 192-193 (1963).
5. Duffy, P. E. & Tennyson, V. M. Phase and electron microscopic observations of Lewy bodies and melanin granules in the substantia nigra and locus coeruleus in Parkinson's disease. J. Neuropathol. Exp. Neurol. 24, 398-414 (1965). Using electron microscopy, Lewy bodies are shown to contain abnormal filaments.
6. Rewcastle, N. B. & Ball, M. J. Electron microscopic structure of the 'incluston bodies' in Pick's disease. Neurology 18, 1205-1213 (1968).
7. Polymeropoulos, M. H. et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047 (1997). A missense mutation in the α-synuclein gene (A53T) causes early-onset familial Parkinson's disease in the Contursi kindred. The first known genetic cause of Parkinson's disease.
8. Spillantini, M. G. et al. α-Synuclein in Lewy bodies. Nature 388, 839-840 (1997). The first description of the presence of α-synuclein in Lewy bodies and Lewy neurites of idiopathic Parkinson's disease and dementia with Lewy bodies.
9. Lavedan, C. The synuclein family. Genome Res. 2, 871-880 (1998).
10. Clayton, D. F. & George, J. M. Synucleins in synaptic plasticity and neurodegenerative disorders. J. Neurosci. Res. 58, 120-129 (1999).
11. Maroteaux, L., Campanelli, J. T. & Scheuer, R. H. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic terminal. J. Neurosci. 8, 2804-2815 (1988).
12. Tobe, T. et al. Cloning and characterization of the cDNA encoding a novel brain-specific 14-kDa protein. J. Neurochem. 59, 1624-1629 (1992).
13. Uéda, K. et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl Acad. Sci. USA 90, 11282-11286 (1993).
14. Bayer, T. A. et al. α-Synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease β-amyloid plaque cores. Neurosci. Lett. 266, 213-216 (1999).
15. Jakes, R., Spillantini, M. G. & Goedert, M. Identification of two distinct synucleins from human brain. FEBS Lett. 345, 27-32 (1994).
16. Ji, H. et al. Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res. 57, 759-764 (1997).
17. Buchman, V. L. et al. Persyn, a member of the synuclein family, has a distinct pattern of expression in the developing nervous system. J. Neurosci. 18, 9335-9341 (1998).
18. Davidson, W. S., Jonas, A., Clayton, D. F. & George, J. M. Stabilization of α-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273, 9443-9449 (1998).
19. Jensen, P. H., Nielsen, M. H., Jakes, R., Dotti, C. G. & Goedert, M. Binding of α-synuclein to rat brain vesicles is abolished by familial Parkinson's disease mutation. J. Biol. Chem. 273, 26292-26294 (1998).
20. McLean, P. J., Kawamata, H., Ribich, S. & Hyman, B. T. Membrane association and protein conformation of α-synuclein in intact neurons. J. Biol. Chem. 275, 8812-8816 (2000).
21. Jo, E., McLaurin, J. A., Yip, C. M., St George-Hyslop, P. H. & Fraser, P. E. α-Synuclein membrane interactions and lipid specificity. J. Biol. Chem. 275, 34328-34334 (2000).
22. Perrin, R. J., Woods, W. S., Clayton, D. F. & George, J. M. Interaction of human α-synuclein and Parkinson's disease variants with phospholipids. J. Biol. Chem. 275, 34393-34398 (2000).
23. Eliezer, D., Kutluay, E., Bussell, R. & Browne, G. Conformational properties of α-synuclein in its free and lipid-associated states. J. Mol. Biol. 307, 1061-1073 (2001).
24. Jenco, J. M., Rawlingson, A., Daniels, B. & Morris, A. J. Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by α-and β-synuclein. Biochemistry 37, 4901-4909 (1998).
25. Okochi, M. et al. Constitutive phosphorylation of the Parkinson's disease-associated α-synuclein. J. Biol. Chem. 275, 390-397 (2000).
26. Pronin, A. N., Morris, A. J., Surguchov, A. & Benovic, J. L. Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J. Biol. Chem. 275, 26515-26522 (2000).
27. Engelender, S. et al. Synphilin-1 associates with α-synuclein and promotes the formation of cytosolic inclusions. Nature Genet. 22, 110-114 (1999).
28. Wakabayashi, K. et al. Synphilin-1 is present in Lewy bodies in Parkinson's disease. Ann. Neurol. 47, 521-523 (2000).
29. Abeliovich, A. et al. Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239-252 (2000).
30. Parkinson, J. An Essay on the Shaking Palsy (Sherwood, Neety & Jones, London, 1817). The first clinical description of the disease that became known as Parkinson's disease.
31. Tretiakoff, C. Contribution à l'étude de l'anatomie pathologique du locus niger de Soemmering avec quelques déductions relatives à la pathogénie des troubles du tonus musculaire et de la maladie de Parkinson. Thesis, Univ. Paris (1919). The first description of pathology in the substantia nigra in Parkinson's disease. Proposal that the inclusions be named after F. Lewy.
32. Hassler, R. Zur Pathologie der Paralysis agitans und des postenzephalitischen Parkinsonismus. J. Psychol. Neurol. 48, 387-486 (1938).
33. Forno, L. S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55, 259-272 (1996).
34. Langston, J. W., Ballard, P., Tetrud, J. & Irwin, I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979-980 (1983).
35. Markey S. P. et al. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 311, 464-467 (1984).
36. +): identification of a metabolite of MPTP. a toxin selective to the substantia nigra. Neurosci. Lett. 48, 87-92 (1984).
37. Javitch, J. A., D'Amato, R. J., Strittmatter, S. M. & Snyder, S. H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxixity. Proc. Natl Acad. Sci. USA 82, 2173-2177 (1985).
38. Nicklas, W. J., Vyas, I. & Heikkila, R. E. Inhibition of NADP-linked oxidation of brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36, 2503-2508 (1985).
39. Langston, J. W. et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phehyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 46, 598-605 (1999).
40. Golbe, L. I. et al. A large kindred with autosomal dominant Parkinson's disease. Ann. Neurol. 27, 276-282 (1990). Description of an early-onset familial form of Parkinson's disease with autopsy-confirmed Lewy body pathology in the Contursi kindred.
41. Denson, M. A. & Wszolek, Z. K. Familial parkinsonism: our experience and a review of the literature. Parkinsonism Related Disord. 1, 1-8 (1995).
42. Denson, M. A. et al. Familial parkinsonism, dementia, and Lewy body disease: study of family G. Ann. Neurol. 42, 638-643 (1997).
43. Muenter, M. D. et al. Hereditary form of parkinsonism-dementia. Ann. Neurol. 43, 768-781 (1998).
44. Mizutani, T. et al. Familial parkinsonism and dementia with ballooned neurons, argyrophilic inclusions, atypical neurofibrillary tangles, tau-negative astrocytic fibrillary tangles, and Lewy bodies. Acta Neuropathol. 95, 15-27 (1998).
45. Polymeropoulos, M. H. et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 274, 1197-1199 (1996).
46. Athanassiadou, A. et al. Genetic analysis of families with Parkinson disease that carry the Ala53Thr mutation in the gene encoding α-synuclein. Am. J. Hum. Genet. 65, 555-558 (1999).
47. Krüger, R. et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nature Genet. 18, 106-108 (1998). A second mutation in the α-synuclein gene (A30P) in a family with early-onset Parkinson's disease.
48. Krüger, R. et al. Increased susceptibility to sporadic Parkinson's disease by a certain combined α-synuclein/apolipoprotein E genotype. Ann. Neurol. 45, 611-617 (1999).
49. Tan, E. K. et al. Polymorphism of NACP-Rep1 in Parkinson's disease: an etiologic link with essential tremor? Neurology 54, 1195-1198 (2000).
50. Arima, K. et al. Immunoelectronmicroscopic demonstration of NACP/α-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies. Brain Res. 808, 93-100 (1998).
51. Crowther, R. A., Daniel, S. E. & Goedert, M. Characterisation of isolated α-synuclein filaments from substantia nigra of Parkinson's disease brain. Neurosci. Lett. 292, 128-130 (2000).
52. Kosaka, K. Lewy bodies in cerebral cortex. Report of three cases. Acta Neuropathol. 42, 127-134 (1978).
53. Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M. & Goedert, M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl Acad. Sci. USA 95, 6469-6473 (1998).
54. Baba, M. et al. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879-884 (1998).
55. Serpell, L. C., Berriman, J., Jakes, R., Goedert, M. & Crowther, R. A. Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross-β conformation. Proc. Natl Acad. Sci. USA 97, 4897-4902 (2000).
56. Campbell, B. C. et al. Accumulation of insoluble α-synuclein in dementia with Lewy bodies. Neurobiol. Dis. 7, 192-200 (2000).
57. Iwanaga, K. et al. Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases. Neurology 52, 1269-1271 (1999).
58. Arai, K., Kato, N., Kashiwado, K. & Hattori, T. Pure autonomic failure in association with human α-synucleinopathy. Neurosci. Lett. 296, 171-173 (2000).
59. Kaufmann, H., Hague, K. & Perl, D. Accumulation of α-synuclein in autonomic nerves in autonomic failure. Neurology 56, 980-981 (2001).
60. Forno, L. S. Concentric hyaline intraneuronal inclusions of Lewy type in the brain of elderly persons (50 incidental cases): relationship to parkinsonism. J. Am. Geriat. Soc. 17, 557-575 (1969).
61. Gibb, W. R. G. & Lees, A. J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiat. 51, 745-752 (1988).
62. Lippa, C. F. et al. Lewy bodies contain altered α-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am. J. Pathol. 153, 1365-1370 (1998).
63. Lippa, C. F., Schmidt, M. L., Lee, V. M.-Y. & Trojanowski, J. Q. Antibodies to α-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Ann. Neurol. 45, 353-357 (1999).
64. Tu, P.-H. et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α-synuclein. Ann. Neurol. 44, 415-422 (1998).
65. Yamazaki, M. et al. α-Synuclein inclusions in amygdala in the brains of patients with the parkinsonism-dementia complex of Guam. J. Neuropathol. Exp. Neurol. 59, 585-591 (2000).
66. Spira, P. J. et al. Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr α-synuclein mutation. Ann. Neurol. 49, 313-319 (2001).
67. Gasser, T. et al. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nature Genet. 18, 262-265 (1998).
68. Farrer, M. et al. A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor. Hum. Mol. Genet. 8, 81-85 (1999).
69. Gwinn-Hardy, K. et al. Distinctive neuropathology revealed by α-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p. Acta Neuropathol. 99, 663-672 (2000).
70. Lerov, E. et al. The ubiquitin pathway in Parkinson's disease. Nature 395, 451-452 (1998).
71. Kitada, T. et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608 (1998). Identification of mutations in the parkin gene as a genetic cause of autosomal recessive juvenile parkinsonism (AR-JP).
72. Lücking, C. B. et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N. Engl. J. Med. 342, 1560-1567 (2000).
73. Shimura, H. et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nature Genet. 25, 302-305 (2000).
74. Imai, Y., Soda, M. & Takahashi, R. Parkin suppresses unfolded protein stree-induced cell death through its E3 ubiquitin-protein ligase activity. J. Biol. Chem. 275, 35661-35664 (2000).
75. Zhang, T. et al. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein. CDCrel-1. Proc. Natl Acad. Sci. USA 97, 13354-13359 (2000).
76. Takahashi, H. et al. Familial juvenile parkinsonism: clinical and pathological study in a family. Neurology 44, 437-441 (1994).
77. Mori, H. et al. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 51, 890-892 (1998).
78. Van de Warrenburg, B. P. C. et al. Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 56, 555-557 (2001).
79. Valente, E. M. et al. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on chromosome 1p35-36. Am. J. Hum. Genet. 68, 895-900 (2001).
80. Wakabayashi, K., Yoshimoto, M., Tsuji, S. & Takahashi, H. α-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci. Lett. 249, 180-182 (1998). This and references 64 and 81-83 showed, at about the same time, the presence of α-synuclein in the neuropathological lesions that define multiple system atrophy.
81. Mezey, E. at al. α-Synuclein in neurodegenerative disorders: murderer or accomplice? Nature Med. 4, 755-757 (1998).
82. Spillantini, M. G. et al. Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett. 251, 205-208 (1998).
83. Gai, W. P., Power, J. H., Blumbergs, P. C. & Blessing, W. W. Multiple system atrophy: a new α-synuclein disease? Lancet 352, 547-548 (1998).
84. Wakabayashi, K. et al. Accumulation of α-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol. 96, 445-452 (1998).
85. Papp, M. I., Kahn, J. E. & Lantos, P. L. Glial cytopasmic inclusions in the CNS of patients with multiple system atrophy. J. Neurol. Sci. 94, 79-100 (1989). The first description of the defining neuropathological characteristics of multiple system atrophy.
86. Lantos, P. L. The definition of multiple system atrophy: a review of recent developments. J. Neuropathol. Exp. Neurol. 57, 1099-1111 (1998).
87. Wenning, G. K., Quinn, N., Magalhaes, M., Mathias, C. & Daniel, S. E. 'Minimal change' multiple system atrophy. Mov. Disord. 9, 161-166 (1994).
88. Dickson, D. W. et al. Widespread alterations of α-synuclein in multiple system atrophy. Am. J. Pathol. 155, 1241-1251 (1999).
89. Campbell, B. C. V. et al. The solubility of α-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. J. Neurochem. 76, 87-96 (2001).
90. Weinreb, P. H., Zhen, W., Poon, A. W., Conway, K. A. & Lansbury, P. T. NACP, a protein implicated in Alzheimer's disease and teaming, is natively unfolded. Biochemistry 35, 13709-13715 (1996).
91. Crowther, R. A., Jakes, R., Spillantini, M. G. & Goedert, M. Synthetic filaments assembled from C-terminally truncated α-synuclein. FEBS Lett. 436, 309-312 (1998).
92. Conway, K. A., Harper, J. D. & Lansbury, P. T. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson's disease. Nature Med. 4, 1318-1320 (1998).
93. El-Agnaf, O. M. A., Jakes, R., Curran, M. D. & Wallace, A. Effects of the mutations AlaSO to Pro and Ala53 to Thr on the physical and morphological properties of α-synuclein protein implicated in Parkinson's disease. FEBS Lett. 440, 67-70 (1998).
94. Giasson, B. I., Uryu, K., Trojanowski, J. Q. & Lee, V. M.-Y. Mutant and wild-type human α-synuclein assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274, 7619-7622 (1999).
95. Narhi, L. et al. Parkinson's disease mutations accelerate α-synuclein aggregation. J. Biol. Chem. 274, 9843-9846 (1999).
96. Wood, S. J. et al. α-Synuclein fibrillogenesis is nucleation-dependent. J. Biol. Chem. 274, 19509-19512 (1999).
97. Conway, K. A. et al. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl Acad. Sci. USA 97, 571-576 (2000).
98. Conway, K. A., Harper, J. D. & Lansbury, P. T. Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39, 2552-2563 (2000).
99. Biere, A. L. et al. Parkinson's disease-associated α-synuclein is more fibrillogenic than β-and γ-synuclein and cannot cross-seed its homologs. J. Biol. Chem. 275, 34574-34579 (2000).
100. Giasson, B. I., Murray, I. V. J., Trojanowski, J. Q. & Lee, V. M.-Y. A hydrophobic stretch of 12 amino acid residues in the middle of α-synuclein is essential for filament assembly. J. Biol. Chem. 276, 2380-2386 (2001).
101. Masliah, E. et al. Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265-1269 (2000).
102. Van der Putten, H. et al. Neuropathology in mice expressing human α-synuclein. J. Neurosci. 20, 6021-6029 (2000).
103. Kahle, P. J. et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant α-synuclein in human and transgenic mouse brain. J. Neurosci. 20, 6365-6373 (2000).
104. Feany, M. B. & Bender, W. W. A Drosophila model of Parkinson's disease. Nature 404, 394-398 (2000). The expression of wild-type and mutant human α-synuclein in nerve cells of Drosophila results in the formation of α-synuclein inclusions, the degeneration of some dopamine nerve cells, and the appearance of locomotor defects.
105. Perutz, M. F. Glutamine repeats and neurodegenerative diseases: molecular aspects. Trends Biochem. Sci. 24, 58-63 (1999).
106. Orr, H. T. Beyond the Qs in the polyglutamine diseases. Genes Dev. 15, 925-932 (2001).
107. Bence, N. F., Sampat, R. M. & Kopito, R. R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292, 1552-1555 (2001).
108. McNaught, K. St. P. & Jenner, P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 297, 191-194 (2001).
109. Betarbet, R. et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature Neurosci. 3, 1301-1306 (2000). The chronic administration of rotenone to rats results in the degeneration of dopamine nerve cells in the substantia nigra and the formation of α-synuclein-positive filamentous inclusions that resemble Lewy bodies.
110. Hensley, K. et al. Interaction of α-phenyl-N-tert-butyl nitrone and alternative electron acceptors with complex I indicates a substrate reduction site upstream from the rotenone binding site. J. Neurochem. 71, 2549-2557 (1998).
111. Ostrerova-Golts, N. et al. The A53T α-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci. 20, 6048-6054 (2000).
112. Uversky, V. N., Li, J. & Fink, A. K. Evidence for a partially folded intermediate in α-synuclein fibril formation. J. Biol. Chem. 276, 10737-10744 (2001).
113. Hsu, L. J. et al. α-Synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 157, 401-410 (2000).
114. Olanow, C. W. & Tatton, W. G. Etiology and pathogenesis of Parkinson's disease. Ann. Rev. Neurosci. 22, 123-144 (1999).
115. Schapira, A. H. V. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1, 1269 (1989).
116. Mizuno, Y. et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Commun. 163, 1450-1455 (1989).
117. Good, P. F., Hsu, A., Werner, P., Perl, D. P. & Olanow, C. W. Protein nitration in Parkinson's disease. J. Neuropathol. Exp. Neurol. 57, 338-342 (1998).
118. Giasson, B. I. et al. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science 290, 985-989 (2000).
119. Montagu, K. A. Catechol compounds in rat tissues and in brains of different animals. Nature 180, 244-245 (1957).
120. Carlsson, A., Lindqvist, M., Magnusson, T. & Waldeck, B. On the presence of 3-hydroxytyramine in brain. Science 127, 471 (1958).
121. Bertler, A. & Rosengren, E. Occurrence and distribution of dopamine in brain and other tissues. Experientia 15, 10-11 (1959).
122. Sano, I. et al. Distribution of catechol compounds in human brain. Bochim. Biophys. Acta 32, 586-587 (1959).
123. Carlsson, A., Lindqvist, M. & Magnusson, T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180, 1200 (1957).
124. Carlsson, A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol. Rev. 11, 490-493 (1959).
125. Ehringer, H. & Hornykiewicz, O. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Ekrankungen des extrapyramidalen Systems. Klin. Wschr. 38, 1236-1239 (1960).
126. Marsden, C. D. Parkinson's disease. Lancer 335, 948-952 (1990).
127. Birkmayer, W. & Hornykiewicz, O. Der L-Doxyphenylalanin effekt bei der Parkinson-Akinese. Wien. Klin. Wschr. 73, 787-788 (1961).
128. Barbeau, A., Sourkes, T. L. & Murphy, G. F. in Monoamines et Système Nerveux Central (ed. De Ajuriaguerra, J.) 247-262 (Masson & Cie., Paris, 1962).
129. Cotzias, G. C., Papavasiliou, P. S. & Fehling, S. Modification of parkinsonism: chronic treatment with L-DOPA. N. Engl. J. Med. 280, 337-345 (1969).